Start here if you're new
what it is
Ionis makes RNA drugs for rare diseases and hopes a few new launches turn years of science into durable sales.
how it gets paid
Last year Ionis Pharm made $944M in revenue. spinraza royalties was the main engine at $310M, or 33% of sales.
why it's growing
Revenue grew 33.8% last year. Q4 2025 revenue was about $203M, down roughly 11% vs. prior year — full-year growth came from earlier quarters and deal economics, not that single print.
what just happened
Ionis posted Q4 EPS of -$1.41, missing a consensus near -$1.23 even as Q4 revenue beat sell-side revenue estimates.
At a glance
B balance sheet — gets the job done, barely
15/100 earnings predictability — expect surprises
4.5% return on capital — nothing to write home about
xvary composite: 43/100 — below average
-$2.00 fy2027 eps est
What they do
Ionis makes RNA drugs for rare diseases and hopes a few new launches turn years of science into durable sales.
Ionis wins because it has an RNA drug engine already on the field, not just in a slide deck. It sells five commercial medicines and generated $944 million in 2025 revenue, up 33.8% vs. prior year. Antisense technology (gene-silencing medicine) → drugs that switch off harmful RNA → so what: if your disease has few treatment options, a working platform buys Ionis more shots on goal.
How they make money
$944M
annual revenue · their business grew +33.8% last year
tryngolza
$108M
up from launch base
spinraza royalties
$310M
mixed
partner revenue
$250M
volatile
commercial portfolio ex-tryngolza
$226M
up
milestones and other
$50M
lumpy
The products that matter
commercialized antisense portfolio
approved drugs
five approved drugs
five commercial medicines validate that the platform can reach patients and payers, and they helped support $944M in total revenue. That matters because many biotech stories never make it past the science fair stage.
platform validated
pharma-funded development engine
partnered pipeline
40+ programs
more than 40 programs spread the bet across multiple shots on goal, while partnerships with Biogen, Novartis, Roche, and AstraZeneca add external validation. In biotech, good counterparties are a form of due diligence.
scale matters
future approval optionality
next wave candidates
~$13B market cap
a roughly $13B valuation on $944M of revenue tells you the market is still underwriting future launches. If the next readouts land, that premium makes sense. If they do not, it starts to look expensive fast.
priced for progress
Key numbers
-$2.00
fy2027 eps est
$1B
fy2029 rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 30 / 100
- long-term debt $859M (6% of capital)
- net profit margin negative (GAAP) — 2025 was still a loss-making year despite higher revenue
- return on equity not meaningful — GAAP losses make ROE a noisy headline metric here
B — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in IONS 3 years ago → it's now worth $20,320.
The index would have given you $13,880.
source: institutional data · total return
What just happened
missed estimates
Ionis posted Q4 EPS of -$1.41, missing a consensus near -$1.23 even as Q4 revenue beat expectations.
Q4 2025 revenue was about $203M, down roughly 11% vs. prior year. The problem is simple: the full-year revenue story improved, but quarterly GAAP losses can still widen when R&D and program spend dominate.
~$203M
revenue (Q4)
-$1.41
eps (Q4)
n/a
n/a
the number that mattered
EPS was about $0.18 worse than a ~-$1.23 consensus on a per-share loss — a double-digit percentage miss on the loss — which matters because this stock is priced for cleaner execution than Ionis just delivered.
-
ionis pharmaceuticals stock has been holding up well, after soaring to new highs in recent months.recall that the equity rallied last year, following the approval/launch of tryngolza (olezarsen), a therapy for fcs (familial chylomicronemia syndrome, a rare but severe genetic disease that causes buildup of triglycerides).
-
investors also applauded positive data back in september from ground-breaking pivotal phase iii studies, showing the same compound to lower triglycerides and life-threatening pancreatitis episodes.just as 2025 was coming to a close, ionis was on track to submit a new drug application with the fda. the good news should keep coming, as more potential drug launches are on tap for 2026 and 2027, auguring well for growth.
-
indeed, in addition to olezarsen for fcs with acute pancreatitis, ionis is moving forward with a regulatory filing on zilganersen, as a treatment for alexander disease (a progressive, often fatal, neurological disorder).
-
both of these, which are ionis-owned, could get approval in 2026.four additional drug launches (partner-driven) could come down the pike in 2027, targeting cardiovascular and metabolic disease. we’re encouraged by a number of other assets in the r&d pipeline with vast growth potential, including ion582, for angelman syndrome (a severe neurological disorder) and ion337 for dravet syndrome (genetic epilepsy).
-
in the meantime, ionis’ newer drugs are flexing their sales muscles.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is pipeline clinical failure in a 40+ program antisense portfolio.
med
future readouts do not match the platform promise
Ionis has five commercial medicines and 40+ programs, which gives you breadth. It also means there are many chances for disappointment to arrive one headline at a time.
At roughly $13B in market value on $944M of revenue, the stock already prices in more than the current commercial base.
med
revenue growth still fails to become reliable earnings
Revenue grew 33.8% from last year, yet fy2027 EPS is still estimated at -$2.00 and trailing p/e is not meaningful.
That gap is the entire debate. If the company keeps growing without producing durable profits, the valuation argument gets thinner.
med
the stock is built for sharp moves, not smooth compounding
Price stability is 30 / 100, and the 52-week range spans $24 to $87. That is a huge spread for a company with a B balance sheet and a middle-of-the-pack risk rank.
You can be right on the long-term science and still sit through violent repricing if sentiment on biotech or a single program turns.
With $944M in revenue, a ~$13B market cap, and a 15 / 100 predictability score, this remains a pipeline-priced stock more than a settled operating business.
source: institutional data · regulatory filings · risk analysis
Pay attention to
risk
pipeline readouts need to keep landing
Five commercial medicines validate the platform, but 40+ programs are what keep the premium story alive. In this name, clinical momentum is not a side note. It is the plot.
metric
whether $944M revenue can turn into real earnings
Revenue grew 33.8% from last year, but fy2027 EPS is still estimated at -$2.00. You want that gap moving in the right direction.
trend
institutional buying staying in place
Two consecutive quarters of net buying, including 241 buyers versus 154 sellers in 3q2025, suggest large holders still want exposure.
calendar
the next public data point that proves the platform again
This page already references positive phase 2 ION22 results. The next update needs to add to that stack, not just repeat the old thesis.
Analyst rankings
earnings predictability
15 / 100
in human-speak, analysts think this company can surprise you — and not always in the relaxing direction.
risk rank
3
That puts Ionis around the middle of the safety pack. Not fragile, not defensive.
price stability
30 / 100
The shares have been volatile. A $24–$87 range tends to do that.
source: institutional data
Institutional activity
institutions have been net buying for 2 consecutive quarters — 241 buyers vs. 154 sellers in 3q2025. total institutional holdings: 0.2B shares. net buying for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$27
$103
$81
current price
$65
target midpoint · 19% from current · 3-5yr high: $95 (+20% · 4% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive